Xencor Inc

詳細情報 Xencor Inc 企業名

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

企業情報

企業コードXNCR

会社名Xencor Inc

上場日Dec 03, 2013

最高経営責任者「CEO」Dr. Bassil I. Dahiyat, Ph.D.

従業員数250

証券種類Ordinary Share

決算期末Dec 03

本社所在地465 N. Halstead St.

都市PASADENA

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号91107

電話番号16263055900

ウェブサイトhttps://xencor.com/

企業コードXNCR

上場日Dec 03, 2013

最高経営責任者「CEO」Dr. Bassil I. Dahiyat, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

212.96K

+10.45%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+47.02%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-10.16%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+305.17%

Mr. Todd E. Simpson

Independent Director

13.69K

--

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+427.04%

Dr. Kevin C. Gorman, Ph.D.

Independent Director

--

Dr. Bassil I. Dahiyat, Ph.D.

President, Chief Executive Officer, Founder and Director

--

Dr. A. Bruce Montgomery, M.D.

Lead Independent Director

--

Dr. Ellen Gwen Feigal, M.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

212.96K

+10.45%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+47.02%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-10.16%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+305.17%

Mr. Todd E. Simpson

Independent Director

13.69K

--

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+427.04%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Royalties

18.23M

55.70%

Milestone

14.50M

44.30%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

Royalties

18.23M

55.70%

Milestone

14.50M

44.30%

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

15.09%

PRIMECAP Management Company

13.71%

The Vanguard Group, Inc.

12.12%

EcoR1 Capital, LLC

8.63%

T. Rowe Price Associates, Inc.

5.38%

Other

45.06%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

15.09%

PRIMECAP Management Company

13.71%

The Vanguard Group, Inc.

12.12%

EcoR1 Capital, LLC

8.63%

T. Rowe Price Associates, Inc.

5.38%

Other

45.06%

種類

株主統計

比率

Investment Advisor

59.58%

Investment Advisor/Hedge Fund

31.25%

Hedge Fund

15.77%

Research Firm

2.93%

Venture Capital

1.94%

Individual Investor

1.32%

Pension Fund

1.03%

Bank and Trust

0.36%

Sovereign Wealth Fund

0.25%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

437

81.46M

114.46%

-1.77M

2025Q1

459

80.70M

113.40%

-3.00M

2024Q4

454

76.54M

108.64%

-2.55M

2024Q3

455

73.66M

105.55%

+3.66M

2024Q2

436

65.64M

106.20%

-4.06M

2024Q1

431

66.91M

108.52%

-498.74K

2023Q4

420

65.39M

107.20%

-1.62M

2023Q3

417

65.14M

107.37%

-1.33M

2023Q2

422

64.91M

107.12%

-2.55M

2023Q1

418

65.89M

109.12%

+515.07K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

10.74M

15.09%

-230.83K

-2.10%

Mar 31, 2025

PRIMECAP Management Company

9.76M

13.71%

+776.58K

+8.64%

Mar 31, 2025

The Vanguard Group, Inc.

7.88M

11.08%

-118.90K

-1.49%

Mar 31, 2025

EcoR1 Capital, LLC

6.14M

8.63%

--

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.83M

5.38%

-108.25K

-2.75%

Mar 31, 2025

State Street Global Advisors (US)

3.68M

5.18%

+482.80K

+15.08%

Mar 31, 2025

BVF Partners L.P.

2.74M

3.85%

+451.38K

+19.72%

Mar 31, 2025

TCG Crossover Management, LLC

2.45M

3.45%

--

Mar 31, 2025

RTW Investments L.P.

2.40M

3.38%

--

Mar 31, 2025

Dimensional Fund Advisors, L.P.

1.74M

2.44%

+235.86K

+15.71%

Mar 31, 2025

詳細を見る

8.040USD

Xencor Inc

8.040

概要

企業名

金融